RU2712281C1 - Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма - Google Patents

Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма Download PDF

Info

Publication number
RU2712281C1
RU2712281C1 RU2018141291A RU2018141291A RU2712281C1 RU 2712281 C1 RU2712281 C1 RU 2712281C1 RU 2018141291 A RU2018141291 A RU 2018141291A RU 2018141291 A RU2018141291 A RU 2018141291A RU 2712281 C1 RU2712281 C1 RU 2712281C1
Authority
RU
Russia
Prior art keywords
compound
steroid
therapy
patients
asthma
Prior art date
Application number
RU2018141291A
Other languages
English (en)
Russian (ru)
Inventor
Владимир Евгеньевич Небольсин
Original Assignee
Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2018141291A priority Critical patent/RU2712281C1/ru
Application filed by Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" filed Critical Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс"
Priority to BR112021009801A priority patent/BR112021009801A2/pt
Priority to EA201992646A priority patent/EA201992646A1/ru
Priority to CN202210260820.9A priority patent/CN114652721A/zh
Priority to GEAP201915712A priority patent/GEP20237467B/en
Priority to GEAP201915619A priority patent/GEP20247643B/en
Priority to CN201980076564.4A priority patent/CN113164464A/zh
Priority to MDA20210050A priority patent/MD4844C1/ro
Priority to EP22210617.1A priority patent/EP4218758A3/en
Priority to IL297533A priority patent/IL297533A/en
Priority to MX2021006032A priority patent/MX2021006032A/es
Priority to MYPI2021002768A priority patent/MY209416A/en
Priority to GEAP202215712A priority patent/GEAP202215712A/en
Priority to AU2019384626A priority patent/AU2019384626A1/en
Priority to MDA20210032A priority patent/MD4851C1/ro
Priority to JP2021528866A priority patent/JP2022508167A/ja
Priority to KR1020217019084A priority patent/KR20210095652A/ko
Priority to EP19886166.8A priority patent/EP3884945A4/en
Priority to GEAP202415619A priority patent/GEAP202415619A/en
Priority to US17/296,539 priority patent/US20220362230A1/en
Priority to PCT/RU2019/050225 priority patent/WO2020106191A1/ru
Priority to KR1020227040632A priority patent/KR20220162821A/ko
Priority to CA3120882A priority patent/CA3120882A1/en
Application granted granted Critical
Publication of RU2712281C1 publication Critical patent/RU2712281C1/ru
Priority to CL2021001316A priority patent/CL2021001316A1/es
Priority to PH12021551152A priority patent/PH12021551152A1/en
Priority to IL283317A priority patent/IL283317A/en
Priority to MX2022013503A priority patent/MX2022013503A/es
Priority to ZA2021/04247A priority patent/ZA202104247B/en
Priority to CL2022000683A priority patent/CL2022000683A1/es
Priority to ZA2022/10444A priority patent/ZA202210444B/en
Priority to AU2022256212A priority patent/AU2022256212B2/en
Priority to JP2022184210A priority patent/JP7518997B2/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018141291A 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма RU2712281C1 (ru)

Priority Applications (32)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
EP19886166.8A EP3884945A4 (en) 2018-11-23 2019-11-22 GLUTARIMIDE DERIVATIVE TO OVERCOME RESISTANCE TO STEROIDS
CN202210260820.9A CN114652721A (zh) 2018-11-23 2019-11-22 戊二酰亚胺衍生物用于克服类固醇抗性和治疗与异常干扰素γ信号传导相关的疾病的用途
GEAP201915712A GEP20237467B (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods and treatment of diseases associated with aberrant signaling of interferon pi3k-gamma
GEAP201915619A GEP20247643B (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods
CN201980076564.4A CN113164464A (zh) 2018-11-23 2019-11-22 用于克服类固醇抗性的戊二酰亚胺衍生物
MDA20210050A MD4844C1 (ro) 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
EP22210617.1A EP4218758A3 (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods
IL297533A IL297533A (en) 2018-11-23 2019-11-22 Consequences of glutrimide for use in the treatment of cough
MX2021006032A MX2021006032A (es) 2018-11-23 2019-11-22 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma.
MYPI2021002768A MY209416A (en) 2018-11-23 2019-11-22 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
GEAP202215712A GEAP202215712A (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods and treatment of diseases associated with aberrant signaling of interferon pi3k-gamma
AU2019384626A AU2019384626A1 (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods
MDA20210032A MD4851C1 (ro) 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
BR112021009801A BR112021009801A2 (pt) 2018-11-23 2019-11-22 Uso de derivado da glutarimida para superar resistência a esteroide e tratar doenças associadas, com a sinalização aberrante do interferon gama
KR1020217019084A KR20210095652A (ko) 2018-11-23 2019-11-22 스테로이드에 대한 내성을 극복하기 위한 글루타르이미드 유도체
US17/296,539 US20220362230A1 (en) 2018-11-23 2019-11-22 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
EA201992646A EA201992646A1 (ru) 2018-11-23 2019-11-22 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
GEAP202415619A GEAP202415619A (en) 2018-11-23 2019-11-22 Glutarimide derivative for overcoming resistance to steriods
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам
KR1020227040632A KR20220162821A (ko) 2018-11-23 2019-11-22 스테로이드에 대한 내성을 극복하기 위한 글루타르이미드 유도체
CA3120882A CA3120882A1 (en) 2018-11-23 2019-11-22 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
JP2021528866A JP2022508167A (ja) 2018-11-23 2019-11-22 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用
CL2021001316A CL2021001316A1 (es) 2018-11-23 2021-05-19 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma.
PH12021551152A PH12021551152A1 (en) 2018-11-23 2021-05-20 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
IL283317A IL283317A (en) 2018-11-23 2021-05-20 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
MX2022013503A MX2022013503A (es) 2018-11-23 2021-05-21 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.
ZA2021/04247A ZA202104247B (en) 2018-11-23 2021-06-21 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
CL2022000683A CL2022000683A1 (es) 2018-11-23 2022-03-21 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma. (divisional de solicitud 202101316)
ZA2022/10444A ZA202210444B (en) 2018-11-23 2022-09-21 Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
AU2022256212A AU2022256212B2 (en) 2018-11-23 2022-10-21 Glutarimide derivative for overcoming resistance to steriods
JP2022184210A JP7518997B2 (ja) 2018-11-23 2022-11-17 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Publications (1)

Publication Number Publication Date
RU2712281C1 true RU2712281C1 (ru) 2020-01-28

Family

ID=69624712

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма

Country Status (19)

Country Link
US (1) US20220362230A1 (enExample)
EP (2) EP3884945A4 (enExample)
JP (2) JP2022508167A (enExample)
KR (2) KR20220162821A (enExample)
CN (2) CN113164464A (enExample)
AU (2) AU2019384626A1 (enExample)
BR (1) BR112021009801A2 (enExample)
CA (1) CA3120882A1 (enExample)
CL (2) CL2021001316A1 (enExample)
EA (1) EA201992646A1 (enExample)
GE (4) GEAP202215712A (enExample)
IL (2) IL297533A (enExample)
MD (2) MD4851C1 (enExample)
MX (2) MX2021006032A (enExample)
MY (1) MY209416A (enExample)
PH (1) PH12021551152A1 (enExample)
RU (1) RU2712281C1 (enExample)
WO (1) WO2020106191A1 (enExample)
ZA (2) ZA202104247B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2819722C2 (ru) * 2022-03-18 2024-05-23 Общество С Ограниченной Ответственностью "Валента - Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06263640A (ja) * 1991-09-23 1994-09-20 Ruth Korth Ｐａｆ拮抗物質との組合せに於ける好酸球介在性疾患の治療および予防とそれらの効能測定のための方法
WO2007103368A2 (en) * 2006-03-06 2007-09-13 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
WO2015072893A1 (ru) * 2013-11-14 2015-05-21 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
EP3722290B1 (en) * 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
GEAP202115467A (en) * 2017-09-07 2021-10-11 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06263640A (ja) * 1991-09-23 1994-09-20 Ruth Korth Ｐａｆ拮抗物質との組合せに於ける好酸球介在性疾患の治療および予防とそれらの効能測定のための方法
WO2007103368A2 (en) * 2006-03-06 2007-09-13 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
WO2015072893A1 (ru) * 2013-11-14 2015-05-21 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CREED T.J. et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. ther. 2003 Jul 1; 18(1): 65-75. Реферат [on line] [Найдено 19.03.2019] (Найдено из интернет:;www.ncbi.nlm.nih.gov/pubmed/12848627) *
CREED T.J. et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. ther. 2003 Jul 1; 18(1): 65-75. Реферат [on line] [Найдено 19.03.2019] (Найдено из интернет:;www.ncbi.nlm.nih.gov/pubmed/12848627); . *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2819722C2 (ru) * 2022-03-18 2024-05-23 Общество С Ограниченной Ответственностью "Валента - Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями

Also Published As

Publication number Publication date
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
EP4218758A2 (en) 2023-08-02
PH12021551152A1 (en) 2021-10-25
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MX2022013503A (es) 2022-11-16
GEP20237467B (en) 2023-02-10
EA201992646A1 (ru) 2020-05-31
KR20210095652A (ko) 2021-08-02
ZA202210444B (en) 2023-01-25
MD20210032A2 (ro) 2021-09-30
GEAP202415619A (en) 2024-03-11
EP3884945A1 (en) 2021-09-29
CL2022000683A1 (es) 2022-10-28
IL297533A (en) 2022-12-01
BR112021009801A2 (pt) 2022-03-03
IL283317A (en) 2021-07-29
JP2023015333A (ja) 2023-01-31
GEAP202215712A (en) 2022-10-10
GEP20247643B (en) 2024-07-10
MD20210050A2 (ro) 2021-12-31
MY209416A (en) 2025-07-08
ZA202104247B (en) 2023-03-29
AU2022256212B2 (en) 2024-08-15
AU2019384626A1 (en) 2021-07-15
MX2021006032A (es) 2021-07-06
AU2022256212A1 (en) 2022-12-08
CL2021001316A1 (es) 2021-10-29
MD4851B1 (ro) 2023-04-30
CN113164464A (zh) 2021-07-23
EP4218758A3 (en) 2023-08-23
CN114652721A (zh) 2022-06-24
MD4844B1 (ro) 2023-02-28
MD4844C1 (ro) 2023-09-30
WO2020106191A1 (ru) 2020-05-28
US20220362230A1 (en) 2022-11-17
EP3884945A4 (en) 2022-11-23
CA3120882A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
Muehler et al. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis
Yeager et al. Glucocorticoid regulation of the inflammatory response to injury
Hanania Targeting airway inflammation in asthma: current and future therapies
JP6441888B2 (ja) 自己免疫性障害の処置におけるレボセチリジン及びモンテルカストの使用
JP2013518908A5 (enExample)
AU2022256212B2 (en) Glutarimide derivative for overcoming resistance to steriods
WO2022271604A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
US7402578B2 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
JP2016153374A (ja) 炎症性疾患を治療又は予防するための医薬組成物
US9662305B2 (en) Use of bucillamine in the treatment of gout
JP7594124B2 (ja) Ｌｏｕ０６４を使用した治療の方法
JP2022523018A5 (enExample)
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
EA046267B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
OA20849A (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
OA20833A (en) Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
EP4703368A1 (en) Isolithocholic acid derivatives and use thereof
EP4702980A1 (en) Isolithocholic acid for use in the prevention or treatment of inflammatory diseases of the respiratory system
HK40059361A (en) Glutarimide derivative for overcoming resistance to steriods
US20250195552A1 (en) Methods of using avermectin compositions for the treatment of inflammatory disorders and dosing regimens
WO2025221754A1 (en) Upadacitinib for use in the treatment of giant cell arteritis
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
EA049049B1 (ru) Способ определения оптимальной дозы глюкокортикостероидов с одновременным уточнением проведения глюкокортикостероидной терапии у пациентов с коронавирусной инфекцией и сахарным диабетом